Lyndra, Inc. and Allergan Sign a Partnership to Develop Ultra-Long-Acting Oral Products

Lyndra, Inc. (Lyndra) announced today a partnership with Allergan plc to develop orally administered ultra-long-acting (once-weekly) products for the treatment of Alzheimer’s disease. The basis of the collaboration between the Boston-based startup and Allergan is Lyndra’s innovative sustained-release technology, which has the potential to transform drugs typically dosed daily to once-weekly oral dosing.

Most Recent Posts:

MGB GRAPHICS CILP Program 220927 0912 150 POWERPOINT 2

Are you an Innovator? Applications for MGB Commercialization and Inclusive Leadership Program now open

The MGB Commercialization and Inclusive Leadership Program (CILP) is a one-day in-person program on commercial application and…

Read More
whalen kimberly 003502672 high res

Finding a Safer Way to Draw Pediatric Blood Led This Nurse to Innovate

The Blood Shield Transfer device allows safe transfer of pediatric blood to microcontainers and blood gas syringes…

Read More
Blog MGB Implements DexCare image

Mass General Brigham Implements DexCare to Support Care Integration and Advance Digital Health

Collaboration demonstrates Mass General Brigham’s commitment to digital transformation and enhancing patient experience   SEATTLE, Oct. 31, 2022…

Read More